Compare BTCT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTCT | BYSI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 31.4M |
| IPO Year | 2019 | 2016 |
| Metric | BTCT | BYSI |
|---|---|---|
| Price | $1.28 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.4M | 112.1K |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $0.57 |
| 52 Week High | $3.12 | $2.44 |
| Indicator | BTCT | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 48.62 |
| Support Level | $1.13 | $0.58 |
| Resistance Level | $1.89 | $1.25 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 8.75 | 84.84 |
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.